Literature DB >> 19760393

Wanted: early goal-directed therapy for septic shock--dead or alive, but not critically ill!

Andre C Kalil.   

Abstract

Mesh：

Year:  2009        PMID： 19760393     DOI： 10.1007/s00134-009-1655-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  18 in total

1.  Goal-directed therapy for severe sepsis.

Authors:  Samir Sarkar; Yizhak Kupfer; Sidney Tessler
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

2.  Goal-directed therapy for severe sepsis.

Authors:  Paul E Marik; Joseph Varon
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

3.  Early goal-directed therapy reduced mortality and multiorgan dysfunction in severe sepsis or septic shock.

Authors:  Charles Natanson; Robert L Danner
Journal:  ACP J Club       Date:  2002 May-Jun

4.  Meta-analysis under the spotlight: we must differentiate its limitations versus its prejudices.

Authors:  Andre C Kalil
Journal:  Crit Care Med       Date:  2008-11       Impact factor: 7.598

5.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group.

Authors:  L A Stewart; M J Clarke
Journal:  Stat Med       Date:  1995-10-15       Impact factor: 2.373

6.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

7.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

Authors:  R Phillip Dellinger; Jean M Carlet; Henry Masur; Herwig Gerlach; Thierry Calandra; Jonathan Cohen; Juan Gea-Banacloche; Didier Keh; John C Marshall; Margaret M Parker; Graham Ramsay; Janice L Zimmerman; Jean-Louis Vincent; M M Levy
Journal:  Intensive Care Med       Date:  2004-03-03       Impact factor: 17.440

8.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.

Authors: 
Journal:  Circulation       Date:  1998-06-09       Impact factor: 29.690

9.  The strengths and limitations of meta-analyses based on aggregate data.

Authors:  Gary H Lyman; Nicole M Kuderer
Journal:  BMC Med Res Methodol       Date:  2005-04-25       Impact factor: 4.615

10.  Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.

Authors:  Andre C Kalil; Junfeng Sun
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240
View more
  2 in total

1.  Year in review in Intensive Care Medicine 2010: II. Pneumonia and infections, cardiovascular and haemodynamics, organization, education, haematology, nutrition, ethics and miscellanea.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2011-01-12       Impact factor: 17.440

Review 2.  Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).

Authors:  Olaf Penack; Carolin Becker; Dieter Buchheidt; Maximilian Christopeit; Michael Kiehl; Marie von Lilienfeld-Toal; Marcus Hentrich; Marc Reinwald; Hans Salwender; Enrico Schalk; Martin Schmidt-Hieber; Thomas Weber; Helmut Ostermann
Journal:  Ann Hematol       Date:  2014-04-29       Impact factor: 3.673
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.